Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Construction, expression and immunogenicity of a novel anti-hypertension angiotensin II vaccine based on hepatitis A virus-like particle.

Ou X, Guo L, Wu J, Mi K, Yin N, Zhang G, Li H, Sun M.

Hum Vaccin Immunother. 2013 Jun;9(6):1191-9. doi: 10.4161/hv.23940. Epub 2013 Feb 14.

2.

A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.

Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, Nief V, Schellekens C, Sladko K, Roubicek K, Pfister T, Rettenbacher M, Volk HD, Wagner F, Müller P, Jennings GT, Bachmann MF.

J Hypertens. 2007 Jan;25(1):63-72.

PMID:
17143175
3.

Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats.

Koriyama H, Nakagami H, Nakagami F, Osako MK, Kyutoku M, Shimamura M, Kurinami H, Katsuya T, Rakugi H, Morishita R.

Hypertension. 2015 Jul;66(1):167-74. doi: 10.1161/HYPERTENSIONAHA.114.04534. Epub 2015 May 26.

4.

Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.

Lappalainen S, Tamminen K, Vesikari T, Blazevic V.

Hum Vaccin Immunother. 2013 Sep;9(9):1991-2001. doi: 10.4161/hv.25249. Epub 2013 Jun 18.

5.

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.

López-Macías C, Ferat-Osorio E, Tenorio-Calvo A, Isibasi A, Talavera J, Arteaga-Ruiz O, Arriaga-Pizano L, Hickman SP, Allende M, Lenhard K, Pincus S, Connolly K, Raghunandan R, Smith G, Glenn G.

Vaccine. 2011 Oct 13;29(44):7826-34. doi: 10.1016/j.vaccine.2011.07.099. Epub 2011 Aug 2.

PMID:
21816199
6.

[Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].

Zhao YL, Chen YG, Li J, Han GX, Tian C, Liang JL, Li G, Wang ZG, Zhu YG, Tian ZN, Zhang HY, Wan ZJ, Liang ZL, Bi SL.

Zhonghua Liu Xing Bing Xue Za Zhi. 2004 Jun;25(6):470-3. Chinese.

PMID:
15231119
7.

Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.

Arora U, Tyagi P, Swaminathan S, Khanna N.

Vaccine. 2013 Jan 30;31(6):873-8. doi: 10.1016/j.vaccine.2012.12.016. Epub 2012 Dec 20.

PMID:
23261049
8.

Immunogenicity and reactogenicity of the combined hepatitis A and B vaccine in young adults.

Tsai IJ, Chang MH, Chen HL, Ni YH, Lee PI, Chiu TY, Safary A.

Vaccine. 2000 Oct 15;19(4-5):437-41.

PMID:
11027806
9.

[Construction and immunogenicity of recombinant porcine parvovirus-like particles with somatostatin].

Zhang X, Zheng Q, Chen J, Xue G, Hou H, Hou J.

Sheng Wu Gong Cheng Xue Bao. 2010 Aug;26(8):1057-67. Chinese.

PMID:
21090109
10.

Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic.

López-Macías C.

Hum Vaccin Immunother. 2012 Mar;8(3):411-4. doi: 10.4161/hv.18757. Epub 2012 Feb 14. Review.

11.

Assembly and immunogenicity of coronavirus-like particles carrying infectious bronchitis virus M and S proteins.

Liu G, Lv L, Yin L, Li X, Luo D, Liu K, Xue C, Cao Y.

Vaccine. 2013 Nov 12;31(47):5524-30. doi: 10.1016/j.vaccine.2013.09.024. Epub 2013 Oct 5.

PMID:
24099870
12.

Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.

Shen H, Xue C, Lv L, Wang W, Liu Q, Liu K, Chen X, Zheng J, Li X, Cao Y.

Virus Res. 2013 Dec 26;178(2):430-6. doi: 10.1016/j.virusres.2013.09.009. Epub 2013 Sep 17.

PMID:
24050994
14.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

15.

Immunization against angiotensins for the treatment of hypertension.

Maurer P, Bachmann MF.

Clin Immunol. 2010 Jan;134(1):89-95. doi: 10.1016/j.clim.2009.06.003. Epub 2009 Jul 3. Review.

PMID:
19577521
16.

Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens.

Choi JG, Kim MC, Kang HM, Kim KI, Lee KJ, Park CK, Kwon JH, Kim JH, Lee YJ.

Vet Microbiol. 2013 Mar 23;162(2-4):623-30. doi: 10.1016/j.vetmic.2012.11.035. Epub 2012 Nov 29.

PMID:
23265240
17.

[Immunogenicity of experimentally combined hepatitis A and hepatitis E vaccine at different dosage ratio].

Dong C, Dai X, Meng JH.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 Feb;23(2):130-3. Chinese.

PMID:
17286906
18.

Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.

Joshi H, Lewis K, Singharoy A, Ortoleva PJ.

Vaccine. 2013 Oct 1;31(42):4841-7. doi: 10.1016/j.vaccine.2013.07.075. Epub 2013 Aug 9.

PMID:
23933338
19.

Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis.

Nakagami H, Morishita R.

Expert Opin Biol Ther. 2015 Mar;15(3):431-6. doi: 10.1517/14712598.2015.1014791. Epub 2015 Feb 11. Review.

PMID:
25673364
20.

Immunological priming of one dose of inactivated hepatitis A vaccine given during the first year of life in presence of maternal antibodies.

Lagos R, Munoz A, Dumas R, Pichon S, Zambrano B, Levine M, Vidor E.

Vaccine. 2003 Sep 8;21(25-26):3730-3.

PMID:
12922104

Supplemental Content

Support Center